Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 2/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23691126 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP1A2TDP1MAPK1TSHR | |
| SCHEMBL12677158 | 1.00 | ALDH1A1 (0.55) | ALDH1A1CYP1A2TDP1MAPK1TSHR | |
| SCHEMBL13074567 | 0.77 | NPC1 (0.43) | ALDH1A1TDP1MAPK1MAPTKMT2A | |
| SCHEMBL28553516 | 0.77 | CYP1A2 (0.50) | ALDH1A1CYP1A2TDP1MAPK1TSHR | |
| SCHEMBL10030527 | 0.75 | CYP2C9 (0.44) | ALDH1A1TDP1MAPK1MAPTKMT2A | |
| SCHEMBL10438311 | 0.74 | ALDH1A1 (0.55) | ALDH1A1CYP1A2TDP1MAPK1TSHR | |
| SCHEMBL180555 | 0.74 | ALDH1A1 (0.55) | ALDH1A1CYP1A2TDP1MAPK1TSHR | |
| Azobenzene SCHEMBL11328902 | 0.74 | ALDH1A1 (0.86) | ALDH1A1TDP1MAPK1TSHRHSD17B10 | |
| Azobenzene SCHEMBL11328908 | 0.74 | ALDH1A1 (0.86) | ALDH1A1TDP1MAPK1TSHRHSD17B10 | |
| SCHEMBL10152992 | 0.73 | TRPA1 (0.59) | ALDH1A1TDP1MAPK1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220025432-A1 | METHOD FOR FLUORESCENCE LABELING OF BIOLOGICAL MATERIALS, THERMALLY REMOVABLE FLUORESCENT LABELS FOR THIS METHOD, AND METHODS OF THEIR PREPARATION AND USE | FUTURESYNTHESIS SPÓLKA Z O.O. (PL) | 2022-01-27 | — | — | US | disclosed |
| WO-2020117079-A1 | METHOD FOR FLUORESCENCE LABELING OF BIOLOGICAL MATERIALS, THERMALLY REMOVABLE FLUORESCENT LABELS FOR THIS METHOD, AND METHODS OF THEIR PREPARATION AND USE | FUTURESYNTHESIS SPÓLKA Z O.O. (PL) | 2020-06-11 | — | — | WO | disclosed |
| CN-105408328-A | sGC stimulators | IRONWOOD PHARMACEUTICALS INC | 2016-03-16 | — | — | CN | disclosed |
| CN-103313976-A | SGC stimulators | IRONWOOD PHARMACEUTICALS INC | 2013-09-18 | — | — | CN | disclosed |
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220025432-A1 | METHOD FOR FLUORESCENCE LABELING OF BIOLOGICAL MATERIALS, THERMALLY REMOVABLE FLUORESCENT LABELS FOR THIS METHOD, AND METHODS OF THEIR PREPARATION AND USE | DUT, NOP2, NUDT1 | ALDH1A1 509/4885CYP1A2 4578/4885TDP1 141/4885 |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | ALDH1A1 72/4885CYP1A2 630/4885TDP1 1843/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | ALDH1A1 4573/4885CYP1A2 4676/4885TDP1 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.